Sage Journals: Discover world-class research

Abstract

Objective:

Residential is a common treatment setting for youth with high-severity substance use disorders (SUD). This study evaluated the prevalence of psychiatric symptoms and medication for youth in residential SUD treatment.

Methods:

Youth in Massachusetts state licensed and funded SUD residential programs completed questionnaires assessing demographics, primary substance of use, and psychopathology symptoms (Youth Self Report [YSR]/Adult Self Report [ASR]). De-identified medication lists were provided by the programs. Descriptive statistics were used to describe the sample.

Results:

Among the 47 youth who participated, 51.1% were male, 72.3% white, 83% non-Hispanic, mean age 20.7 years. Opioids were the most common primary substance identified by youth (51.1%), and 75% had at least one clinically elevated subscale on the YSR/ASR. Most youth were prescribed at least one medication (89.4%) with a mean of 2.9 medications.

Conclusion:

Youth in SUD residential treatment frequently have clinically elevated psychiatric symptoms, and psychotropic medication was commonly prescribed.

Keywords

adolescent young adult substance use disorder residential medication

Get full access to this article

View all access options for this article.

References

Achenbach

T. M.

Becker

Döpfner

Heiervang

Roessner

Steinhausen

H.-C.

Rothenberger

(2008). Multicultural assessment of child and adolescent psychopathology with ASEBA and SDQ instruments: Research findings, applications, and future directions. Journal of Child Psychology and Psychiatry, and Allied Disciplines, 49(3), 251–275. https://doi.org/10.1111/j.1469-7610.2007.01867.x

Achenbach

T. M.

Ruffle

T. M.

(2000). The child behavior checklist and related forms for assessing behavioral/emotional problems and competencies. Pediatrics in Review, 21(8), 265–271. https://doi.org/10.1542/pir.21-8-265

Achenbach

T. M.

Rescorla

(2001). Manual for the ASEBA school-age forms and profiles. University of Vermont, Research Center for Children, Youth, & Families.

Achenbach

T. M.

Rescorla

(2003). Manual for the ASEBA adult forms and profiles. University of Vermont, Research Center for Children, Youth, & Families.

American Hospital Formulary System. (n.d.). AHFS pharmacologic-therapeutic classification system. Retrieved January 7, 2022, from https://www.oregon.gov/obnm/Documents/Formulary%20Information/AHFSClassificationwithDrugs2019.pdf

Andersson

H. W.

Lauvsnes

A. D. F.

Nordfjærn

(2021). Emerging adults in inpatient substance use treatment: A prospective cohort study of patient characteristics and treatment outcomes. European Addiction Research, 27(3), 206–215. https://doi.org/10.1159/000512156

Bergman

B. G.

Greene

M. C.

Slaymaker

Hoeppner

B. B.

Kelly

J. F.

(2014). Young adults with co-occurring disorders: Substance use disorder treatment response and outcomes. Journal of Substance Abuse Treatment, 46(4), 420–428. https://doi.org/10.1016/j.jsat.2013.11.005

Biederman

Faraone

S. V.

Doyle

Lehman

B. K.

Kraus

Perrin

Tsuang

M. T.

(1993). Convergence of the child behavior checklist with structured interview-based psychiatric diagnoses of ADHD children with and without comorbidity. Journal of Child Psychology and Psychiatry, and Allied Disciplines, 34(7), 1241–1251. https://doi.org/10.1111/j.1469-7610.1993.tb01785.x

Breland-Noble

A. M.

Elbogen

E. B.

Farmer

E. M. Z.

Dubs

M. S.

Wagner

H. R.

Burns

B. J.

(2004). Use of psychotropic medications by youths in therapeutic foster care and group homes. Psychiatric Services (Washington, D.C.), 55(6), 706–708. https://doi.org/10.1176/appi.ps.55.6.706

10.

Carroll Chapman

S. L.

L.-T

. (2013). Substance use among adolescent mothers: A review. Children and Youth Services Review, 35(5), 806–815. https://doi.org/10.1016/j.childyouth.2013.02.004

11.

Chan

Y.-F.

Dennis

M. L.

Funk

R. R.

(2008). Prevalence and comorbidity of major internalizing and externalizing problems among adolescents and adults presenting to substance abuse treatment. Journal of Substance Abuse Treatment, 34(1), 14–24. https://doi.org/10.1016/j.jsat.2006.12.031

12.

Chen

W. J.

Faraone

S. V.

Biederman

Tsuang

M. T.

(1994). Diagnostic accuracy of the child behavior checklist scales for attention-deficit hyperactivity disorder: A receiver-operating characteristic analysis. Journal of Consulting and Clinical Psychology, 62(5), 1017–1025. https://doi.org/10.1037/0022-006X.62.5.1017

13.

Committee on Substance Use and Prevention. (2016). Medication-assisted treatment of adolescents with opioid use disorders. Pediatrics, 138(3), e20161893. https://doi.org/10.1542/peds.2016-1893

14.

Costello

E. J.

Erkanli

Federman

Angold

(1999). Development of psychiatric comorbidity with substance abuse in adolescents: Effects of timing and sex. Journal of Clinical Child Psychology, 28(3), 298–311. https://doi.org/10.1207/S15374424jccp280302

15.

Couwenbergh

van den Brink

Zwart

Vreugdenhil

van Wijngaarden-Cremers

van der Gaag

R. J.

(2006). Comorbid psychopathology in adolescents and young adults treated for substance use disorders: A review. European Child & Adolescent Psychiatry, 15(6), 319–328. https://doi.org/10.1007/s00787-006-0535-6

16.

Danielson

M. L.

Bitsko

R. H.

Ghandour

R. M.

Holbrook

J. R.

Kogan

M. D.

Blumberg

S. J.

(2018). Prevalence of parent-reported ADHD diagnosis and associated treatment among U.S. children and adolescents, 2016. Journal of Clinical Child and Adolescent Psychology: The Official Journal for the Society of Clinical Child and Adolescent Psychology, American Psychological Association, Division 53, 47(2), 199–212. https://doi.org/10.1080/15374416.2017.1417860

17.

Dembo

Belenko

Childs

Wareham

(2009). Drug use and sexually transmitted diseases among female and male arrested youths. Journal of Behavioral Medicine, 32(2), 129–141. https://doi.org/10.1007/s10865-008-9183-2

18.

Fairchild

Hawes

D. J.

Frick

P. J.

Copeland

W. E.

Odgers

C. L.

Franke

Freitag

C. M.

De Brito

S. A.

(2019). Conduct disorder. Nature Reviews. Disease Primers, 5(1), 43. https://doi.org/10.1038/s41572-019-0095-y

19.

Foulds

J. A.

Rouch

Spence

Mulder

R. T.

Sellman

J. D.

(2016). Prescribed psychotropic medication use in patients receiving residential addiction treatment. Alcohol and Alcoholism (Oxford, Oxfordshire), 51(5), 622–623. https://doi.org/10.1093/alcalc/agw025

20.

Griffith

A. K.

Epstein

M. H.

Huefner

J. C.

(2014). Psychotropic medication management within residential treatment centers: Physician opinions about difficulties and barriers. Journal of Child and Family Studies, 23(4), 745–751. https://doi.org/10.1007/s10826-013-9790-6

21.

Hadland

S. E.

Bagley

S. M.

Rodean

Silverstein

Levy

Larochelle

M. R.

Samet

J. H.

Zima

B. T.

(2018). Receipt of timely addiction treatment and association of early medication treatment with retention in care among youths with opioid use disorder. JAMA Pediatrics, 172(11), 1029–1037. https://doi.org/10.1001/jamapediatrics.2018.2143

22.

Hadland

S. E.

Wharam

J. F.

Schuster

M. A.

Zhang

Samet

J. H.

Larochelle

M. R.

(2017). Trends in receipt of buprenorphine and naltrexone for opioid use disorder among adolescents and young adults, 2001-2014. JAMA Pediatrics, 171(8), 747–755. https://doi.org/10.1001/jamapediatrics.2017.0745

23.

Hawkins

E. H.

(2009). A tale of two systems: Co-occurring mental health and substance abuse disorders treatment for adolescents. Annual Review of Psychology, 60, 197–227. https://doi.org/10.1146/annurev.psych.60.110707.163456

24.

Kast

K. A.

Rao

Wilens

T. E.

(2021). Pharmacotherapy for attention-deficit/hyperactivity disorder and retention in outpatient substance use disorder treatment: A retrospective cohort study. The Journal of Clinical Psychiatry, 82(2), 20m13598. https://doi.org/10.4088/JCP.20m13598

25.

King

Beetham

Smith

Englander

Hadland

S. E.

Bagley

S. M.

Korthuis

P. T.

(2023). Treatments used among adolescent residential addiction treatment facilities in the US, 2022. JAMA, 329(22), 1983–1985. https://doi.org/10.1001/jama.2023.6266

26.

Miles

Mericle

Ritter

Reif

(2022). Association of facility characteristics and substance use disorder outcomes at discharge from residential treatment. Journal of Substance Abuse Treatment, 136, 108664. https://doi.org/10.1016/j.jsat.2021.108664

27.

Özgen

Spijkerman

Noack

Holtmann

Schellekens

A. S. A.

van de Glind

Banaschewski

Barta

Begeman

Casas

Crunelle

C. L.

Daigre Blanco

Dalsgaard

Demetrovics

den Boer

Dom

Eapen

Faraone

S. V.

Franck

. . . Hendriks

(2020). International consensus statement for the screening, diagnosis, and treatment of adolescents with concurrent attention-deficit/hyperactivity disorder and substance use disorder. European Addiction Research, 26(4–5), 223–232. https://doi.org/10.1159/000508385

28.

Park

T. W.

Baul

T. D.

Morgan

J. R.

Wilens

T. E.

Yule

A. M.

(2023). Trends in attention-deficit hyperactivity disorder diagnosis and pharmacotherapy among adults with opioid use disorder. Psychiatric Services (Washington, D.C.), appips20220400. https://doi.org/10.1176/appi.ps.20220400

29.

Pavkov

T. W.

Negash

Lourie

I. S.

Hug

R. W.

(2010). Critical failures in a regional network of residential treatment facilities. The American Journal of Orthopsychiatry, 80(2), 151–159. https://doi.org/10.1111/j.1939-0025.2010.01018.x

30.

Racz

S. J.

Saha

Trent

Adger

Bradshaw

C. P.

Goldweber

Cauffman

(2015). Polysubstance use among minority adolescent males incarcerated for serious offenses. Child & Youth Care Forum, 45(2), 205–220. https://doi.org/10.1007/s10566-015-9334-x

31.

Schuman-Olivier

Claire Greene

Bergman

B. G.

Kelly

J. F.

(2014). Is residential treatment effective for opioid use disorders? A longitudinal comparison of treatment outcomes among opioid dependent, opioid misusing, and non-opioid using emerging adults with substance use disorder. Drug and Alcohol Dependence, 144, 178–185. https://doi.org/10.1016/j.drugalcdep.2014.09.009

32.

Society for Adolescent Health and Medicine. (2021). Medication for adolescents and young adults with opioid use disorder. The Journal of Adolescent Health: Official Publication of the Society for Adolescent Medicine, 68(3), 632–636. https://doi.org/10.1016/j.jadohealth.2020.12.129

33.

Spellman

D. F.

Griffith

A. K.

Huefner

J. C.

Wise

McElderry

Leslie

L. K.

(2010). Psychotropic medication management in a residential group care program. Child Welfare, 89(2), 151–167.

34.

Substance Abuse and Mental Health Services Administration (SAMHSA). (2021a). Substance use and mental health indicators in the United States: Results from the 2020 national survey on drug use and health (PEP21-07-01–003). Center for Behavioral Health Statistics and Quality. https://www.samhsa.gov/data/

35.

Substance Abuse and Mental Health Services Administration (SAMHSA). (2021b). Treatment considerations for youth and young adults with serious emotional disturbances/serious mental illnesses and co-occurring substance use (PEP20-06-02–001). National Mental Health and Substance Use Policy Laboratory, Substance Abuse and Mental Health Services Administration.

36.

Terranella

Guy

G. P.

Jr. Mikosz

(2023). Buprenorphine dispensing among youth aged ≤19 years in the United States: 2015–2020. Pediatrics, 151(2), e2022058755. https://doi.org/10.1542/peds.2022-058755

37.

Uchida

Spencer

T. J.

Faraone

S. V.

Biederman

(2018). Adult outcome of ADHD: An overview of results from the MGH longitudinal family studies of pediatrically and psychiatrically referred youth with and without ADHD of both sexes. Journal of Attention Disorders, 22(6), 523–534. https://doi.org/10.1177/1087054715604360

38.

van Wattum

P. J.

Fabius

Roos

Smith

Johnson

. (2013). Polypharmacy reduction in youth in a residential treatment center leads to positive treatment outcomes and significant cost savings. Journal of Child and Adolescent Psychopharmacology, 23(9), 620–627. https://doi.org/10.1089/cap.2013.0014

39.

Wise

B. K.

Cuffe

S. P.

Fischer

(2001). Dual diagnosis and successful participation of adolescents in substance abuse treatment. Journal of Substance Abuse Treatment, 21(3), 161–165. https://doi.org/10.1016/s0740-5472(01)00193-3

Medication Treatment for Youth in Substance Use Disorder Residential Treatment

Abstract

Objective:

Methods:

Results:

Conclusion:

Keywords

Get full access to this article

References